Beacon Equity issues Trading Overview for Chelsea Therapeutics International Limited
The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
(EMAILWIRE.COM, September 28, 2009 ) DALLAS, Texas - BeaconEquity.com announces an investment report featuring Chelsea Therapeutics International Limited (Nasdaq: CHTP).
The investment report on Chelsea Therapeutics International Limited (Nasdaq: CHTP) should be of particular interest to other biotech companies: Abbott Laboratories (NYSE: ABT), Amgen Inc. (Nasdaq: AMGN), Incyte Corp. (Nasdaq: INCY) and Bristol-Myers Squibb Co. (NYSE: BMY).
It is available at: http://www.beaconequity.com/i/CHTP
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Chelsea Therapeutics International Limited (CHTP) engages in the development of acquired products for the treatment of immunological disorders, hypotension and cancers. The Company's lead antifolate compound, CH-1504, is developed with Active Biotech AB to treat autoimmune disease and cancer. The Company also develops Droxodopa for the treatment of neurogenic orthostatic hypotension, which is currently approved in Japan and marketed by Dainippon Sumitomo Pharma Co. Limited.
Message Board Search for CHTP: http://www.boardcentral.com/boards/CHTP
In the report, the analyst notes:
“The United States market for immunological disorders is estimated to reach more than $23.6 billion in 2011, with a growth rate of 17.5% through 2011. And according to the Cancer Market Outlook report published by Business Insights, the market for cancer therapeutic drugs is expected to reach $40.9 billion by 2012. The leading pharmaceuticals engaged in this sector include Genentech, Johnson & Johnson, Abbott Laboratories, Amgen and Roche.
“On September 25, 2009, the Company said in a news release that initial tests of Droxidopa in phase III trials “did not demonstrate a statistically significant improvement relative to placebo.” Droxidopa is intended to treat symptoms of neurogenic orthostatic hypotension, including dizziness or lightheadedness.”
To read the entire report visit: http://www.beaconequity.com/i/CHTP
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
The investment report on Chelsea Therapeutics International Limited (Nasdaq: CHTP) should be of particular interest to other biotech companies: Abbott Laboratories (NYSE: ABT), Amgen Inc. (Nasdaq: AMGN), Incyte Corp. (Nasdaq: INCY) and Bristol-Myers Squibb Co. (NYSE: BMY).
It is available at: http://www.beaconequity.com/i/CHTP
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Chelsea Therapeutics International Limited (CHTP) engages in the development of acquired products for the treatment of immunological disorders, hypotension and cancers. The Company's lead antifolate compound, CH-1504, is developed with Active Biotech AB to treat autoimmune disease and cancer. The Company also develops Droxodopa for the treatment of neurogenic orthostatic hypotension, which is currently approved in Japan and marketed by Dainippon Sumitomo Pharma Co. Limited.
Message Board Search for CHTP: http://www.boardcentral.com/boards/CHTP
In the report, the analyst notes:
“The United States market for immunological disorders is estimated to reach more than $23.6 billion in 2011, with a growth rate of 17.5% through 2011. And according to the Cancer Market Outlook report published by Business Insights, the market for cancer therapeutic drugs is expected to reach $40.9 billion by 2012. The leading pharmaceuticals engaged in this sector include Genentech, Johnson & Johnson, Abbott Laboratories, Amgen and Roche.
“On September 25, 2009, the Company said in a news release that initial tests of Droxidopa in phase III trials “did not demonstrate a statistically significant improvement relative to placebo.” Droxidopa is intended to treat symptoms of neurogenic orthostatic hypotension, including dizziness or lightheadedness.”
To read the entire report visit: http://www.beaconequity.com/i/CHTP
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Contact Information:
Beacon Equity
Jeff Bishop
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Beacon Equity
Jeff Bishop
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
|
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International Equityallianceir.com Penny Stocks to Watch Sign up for hot penny stock picks Gains of 500%+ possible! Premiumstockpicks.com/landing/ Your text Ads & PR Text Ads plus unlimited press releases, One release featured/Day for only $575 per month. Read more on Text Ads & PR Your text Ads Here! Text Ads are only $289 per month. Ads are placed same day. More on Text Ads Advertising |